Document Detail

Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis.
MedLine Citation:
PMID:  18045826     Owner:  NLM     Status:  MEDLINE    
METHODS: Twenty patients (11 PD, 9 HD) on cinacalcet treatment (30-120 mg/day) were studied. Twelve patients (1 PD, 11 HD) who never received cinacalcet were studied as control group. Each patient received a test meal with blood samples at 0, 2 and 4 h. At 0 time, patients in the cinacalcet group received their usual oral dose of this calcimimetic. Plasma concentrations of intact parathyroid hormone (PTH), vasoactive intestinal peptide (VIP), ghrelin, substance P, serotonin, cholecystokinin (CCK) and gastrin were quantified at 0, 2 and 4 h.
RESULTS: No significant differences in baseline concentrations of serum VIP, ghrelin, substance P, serotonine, CCK and gastrin were found between controls and cinacalcet-treated patients. In comparison with the control group, cinacalcet administration was followed by a significant decrease in VIP concentration at 4 h and a significant increase in substance P at 4 h. However, the areas under the curves of all studied gut hormones were similar in both groups.
CONCLUSION: An acute dose of cinacalcet exerts minimal influence on gut hormone responses to a mixed meal in dialysis patients on chronic therapy with this drug. The small but significant differences between control subjects and patients on cinacalcet in VIP and substance P levels at 4 h should be investigated in symptomatic patients.
Juan J Díez; Jose Luis Miguel; Rosa Codoceo; Pedro Iglesias; M Auxiliadora Bajo; Carmen Sánchez; Gloria Del Peso; Fernando Gil; Jorge Martinez-Ara; Pilar González Gancedo; Rafael Selgas
Related Documents :
15118996 - Increased incidence of carotid artery wall changes and associated variables in hemodial...
2974806 - Immune-deficiency in hodgkin's disease (hd): a study of patients and healthy relatives ...
8676826 - Muscle protein turnover in chronic renal failure patients with metabolic acidosis or no...
14733416 - Erythropoietin requirements: a comparative multicenter study between peritoneal dialysi...
23169076 - The natural history of degenerative spondylolisthesis of the cervical spine with 2-7 ye...
6812246 - Factors influencing monocyte recognition of human erythrocyte autoantibodies in vitro.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-11-28
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  23     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-24     Completed Date:  2008-05-01     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  1387-95     Citation Subset:  IM    
Department of Endocrinology, Hospital Ramón y Cajal, Carretera de Colmenar km 9, 28034 Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcium / blood
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Follow-Up Studies
Gastrointestinal Hormones / secretion*
Hyperparathyroidism, Secondary / etiology,  metabolism,  therapy*
Kidney Failure, Chronic / complications,  metabolism,  therapy*
Middle Aged
Naphthalenes / administration & dosage,  therapeutic use*
Parathyroid Hormone / blood
Phosphorus / blood
Renal Dialysis / methods*
Severity of Illness Index
Substance P / blood
Treatment Outcome
Vasoactive Intestinal Peptide / blood
Reg. No./Substance:
0/Gastrointestinal Hormones; 0/Naphthalenes; 0/Parathyroid Hormone; 33507-63-0/Substance P; 37221-79-7/Vasoactive Intestinal Peptide; 7440-70-2/Calcium; 7723-14-0/Phosphorus; UAZ6V7728S/cinacalcet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The prognosis and pathogenesis of severe lupus glomerulonephritis.
Next Document:  Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease...